欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Abemaciclib Metabolites M2_1231930-57-6_产品详情
1231930-57-6
  • Abemaciclib Metabolites M2

  • names:

    Abemaciclib Metabolites M2

  • CAS号:

    1231930-57-6

    MDL Number:
  • MF(分子式): C25H28F2N8 MW(分子量): 478.54
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Abemaciclib Metabolites M2
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM002318-5mg 5mg ¥ 0.00 ¥ 0.00 Backorder
- +
¥ 0.00
YZM002318-1mg 1mg >97% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 1231930-57-6
Inchi
InchiKey
分子式 Formula C25H28F2N8
分子量 Molecular Weight 478.54
溶解度Solubility
性状
储藏条件 Storage conditions 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.
Abemaciclib Metabolites M2(CAS:1231930-57-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Abemaciclib Metabolites M2 为 abemaciclib 的代谢物,为有效的CDK4和CDK6抑制剂,IC50值为 1-3 nM
IntroductionAbemaciclib Metabolites M2 is a metabolite of abemaciclib, acts as a potentCDK4andCDK6inhibitor, withIC50s in the range of 1 nM. Antiancer activity.
Application1
Application2
Application3
Abemaciclib Metabolites M2 为 abemaciclib 的代谢物,为有效的CDK4和CDK6抑制剂,IC50值为 1-3 nM。具有抗肿瘤活性。Abemaciclib Metabolites M2 is a metabolite of abemaciclib, acts as a potentCDK4andCDK6inhibitor, withIC50s in the range of 1-3 nM. Anti-cancer activity[1].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Teresa Burke, et al. Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. Cancer Research. July 2016, 76 (14).
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents